One Blood Test Cannot Summarise Fertility
Anti-Müllerian hormone—AMH—has become one of the most requested and misunderstood tests in reproductive medicine.
Patients may be told that a low result means they cannot become pregnant, that a high result means they have many fertile years remaining, or that a single number determines whether IVF will work.
None of these interpretations is reliable.
AMH is useful. It helps estimate the pool of small growing follicles and can help predict ovarian response to stimulation. It does not count every remaining egg, directly measure egg quality, diagnose infertility by itself, or provide a personal expiry date for natural conception.
At Jinemed, AMH is interpreted alongside age, antral follicle count, menstrual history, previous ovarian response, diagnosis, reproductive goals, and the rest of the fertility evaluation.
The value of the number comes from the clinical decision it informs—not from the fear or reassurance it creates.
Ovarian Reserve Means Quantity, Not Quality
Ovarian reserve refers primarily to the remaining quantity of oocytes and the ovary’s likely response to stimulation.
Egg quality is different. In clinical terms, quality refers to the egg’s potential, after fertilisation and development, to contribute to a live birth. Chromosomal competence is a major part of that potential and is strongly influenced by age.
A younger patient may have low reserve but still produce a competent egg. An older patient may have a high AMH and produce several eggs, while age-related aneuploidy remains important.
This distinction explains why:
- Low AMH does not equal zero pregnancy chance
- Normal AMH does not guarantee a healthy embryo
- High AMH does not stop reproductive ageing
- Age and reserve can point in different directions
Quantity determines how many opportunities may be available in a treatment cycle. Age influences the probability attached to each opportunity.
What AMH Measures Indirectly
AMH is produced by granulosa cells in small ovarian follicles. Its level generally reflects the number of follicles in early stages of development.
AMH can be measured on different days of the cycle and usually varies less than day-3 FSH. It is not perfectly stable. Results may differ because of:
- Laboratory assay and reference range
- Hormonal contraception
- Recent pregnancy
- Ovarian surgery
- Chemotherapy or other gonadotoxic treatment
- PCOS
- Individual biological variation
- Sample or analytical factors
A value should be interpreted using the laboratory’s method and the patient’s circumstances. Repeating a test in another laboratory may be useful when the result is unexpected or likely to have been affected, but frequent testing does not provide precise measurement of monthly egg loss.
AMH is an estimate, not a direct inventory.
Antral Follicle Count Adds an Ultrasound View
Antral follicle count—AFC—is the number of small follicles visible by transvaginal ultrasound, usually assessed early in the cycle or at an appropriate baseline.
AFC helps predict response to ovarian stimulation and can show whether both ovaries are accessible, whether cysts are present, and how follicles are distributed.
Its limitations include:
- Dependence on examiner skill
- Differences in ultrasound equipment and counting method
- Cycle-to-cycle variation
- Difficulty when ovaries are hidden or affected by cysts
- The fact that a visible follicle does not guarantee a mature egg
AMH and AFC often agree, but not always. When they differ, the team should examine the clinical context rather than automatically choosing the more optimistic result.
Neither measure directly assesses chromosome status.
FSH and Estradiol Still Have Contextual Roles
Early-follicular FSH and estradiol have historically been used to assess ovarian reserve.
A markedly elevated FSH can be a specific sign of reduced reserve, but FSH may rise later in reproductive ageing and can vary between cycles. An elevated estradiol level can suppress FSH and make a result appear more reassuring than it is.
These tests may be relevant in selected evaluations, including irregular cycles or suspected ovarian insufficiency. They are generally less sensitive than AMH and AFC for predicting ovarian response.
Adding every reserve test does not always improve prediction. The correct panel is the one needed for the patient’s question.
Age Remains the Strongest Reproductive Variable
Chronological age affects both the number and competence of eggs, but its most clinically important effect is on the probability that an egg is chromosomally capable of sustained development.
The decline is gradual, then becomes more pronounced in the later reproductive years. It does not begin on one birthday, and individuals of the same age do not have identical fertility.
Age influences:
- Natural monthly conception probability
- Miscarriage risk
- Embryo aneuploidy
- Expected live-birth chance with own eggs
- The number of cycles that may be required
- The urgency of delaying treatment
AMH cannot reverse or override these effects.
A patient aged 30 with low AMH and a patient aged 42 with the same AMH do not have the same prognosis. The expected egg number may be similar; the expected competence of those eggs is not.
Low AMH Does Not Diagnose Infertility
AMH is a poor independent predictor of unassisted conception. A person with low AMH may ovulate regularly and conceive naturally. A person with normal AMH may have blocked tubes, severe male factor, endometriosis, or unexplained infertility.
For this reason, AMH should not be used as a general fertility test in people who have not tried to conceive or have no clinical indication for testing.
A low result can create unnecessary panic. A normal result can create false reassurance and delay pregnancy planning.
The test is most useful when the answer will influence treatment selection, stimulation planning, fertility-preservation counselling, or evaluation of ovarian function.
Screening without a clinical question is not the same as prevention.
Low AMH Is Most Predictive of Egg Yield in IVF
In IVF, AMH and AFC help estimate whether the ovaries are likely to produce a low, average, or high number of follicles and eggs in response to medication.
This information can support:
- Starting-dose selection
- Counselling about expected egg numbers
- Planning for possible cancellation or minimal response
- Choice of trigger and monitoring
- Identifying hyperstimulation risk
- Discussing whether more than one collection may be needed
Prediction remains imperfect. A low-AMH patient may respond better than expected; a normal-AMH patient may respond poorly.
Extremely low AMH should not be used by itself to refuse IVF. It should lead to honest discussion about the probability of retrieving few or no eggs, the cost and burden of treatment, and what outcome would make proceeding worthwhile for that patient.
Previous Response Can Be More Informative Than Another Test
When a patient has already undergone ovarian stimulation, the completed cycle provides direct evidence:
- Medication dose and duration
- Follicle recruitment
- Estradiol response where measured
- Eggs retrieved
- Egg maturity
- Fertilisation
- Embryo development
A previous poor response to appropriately administered stimulation confirms diminished functional reserve more directly than repeated reserve testing.
The next plan should examine what can reasonably change. Increasing medication above a certain point may not recruit follicles that were not available.
Another AMH result cannot erase the biological information from the actual cycle.
Diminished Ovarian Reserve Is Not the Same as Primary Ovarian Insufficiency
Diminished ovarian reserve describes a lower egg quantity or reduced expected response relative to age or clinical context. Menstrual cycles may remain regular.
Primary ovarian insufficiency involves loss or marked reduction of ovarian function before age 40, often with irregular or absent cycles and biochemical evidence of ovarian dysfunction. Intermittent ovulation can still occur.
These conditions require different counselling, evaluation, and long-term health considerations.
A low AMH alone does not establish primary ovarian insufficiency. FSH, estradiol, cycle history, symptoms, age, and repeat testing where indicated are needed.
Precise language prevents a reserve result from becoming an incorrect diagnosis of menopause.
Ovarian Surgery Can Change Reserve
Surgery involving the ovaries may reduce functioning tissue, particularly in bilateral disease, repeat surgery, or endometrioma treatment.
Before ovarian surgery, reserve assessment may help inform:
- Surgical indication
- Tissue-preserving technique
- Whether fertility treatment should occur first
- Whether egg or embryo freezing should be discussed
- The risk of a lower postoperative response
The decision should not be made from AMH alone. Symptoms, imaging, suspicion of malignancy, organ risk, age, and the purpose of surgery remain central.
Preserving a number is not more important than treating a necessary medical condition. The aim is to avoid preventable loss of opportunity when timing can be planned.
PCOS and High AMH Require a Different Interpretation
Patients with PCOS often have many small follicles and elevated AMH.
This may predict a strong response to stimulation and increased risk of ovarian hyperstimulation syndrome. It does not guarantee natural ovulation, egg competence, embryo quality, or lifelong fertility.
High AMH can therefore mean:
- More follicles available to respond
- Greater need for careful dosing
- Possible cycle irregularity or anovulation
- Higher hyperstimulation risk
It should not be translated as “excellent fertility” without considering age, ovulation, metabolic health, tubes, semen, and the full diagnosis.
More follicles and more fertility are not synonyms.
AMH and Fertility Preservation
When egg freezing is considered, age is generally more important than AMH for the expected competence of frozen eggs. AMH helps estimate how many eggs might be obtained in a collection.
A younger patient with low AMH may need more than one cycle to store a target number of eggs. An older patient with high AMH may collect more eggs, but each egg still carries age-related limitations.
AMH should not be used to market egg freezing to people with untested fertility. Nor should a low result be used to pressure an immediate commercial decision.
Counselling should include:
- Age at freezing
- Expected egg yield
- Possible number of cycles
- Future thaw, fertilisation, and embryo attrition
- Storage and consent
- Cost
- The fact that stored eggs do not guarantee a child
The purpose is informed planning, not biological insurance language.
AMH Cannot Select an Embryo or Predict Its Chromosomes
AMH is measured before eggs are retrieved. It does not show which egg will fertilise, which embryo will reach blastocyst, or which embryo is euploid.
Lower reserve can reduce the number of embryos available for selection. This may lower the cumulative opportunity to obtain a transferable embryo, especially at older ages. That is a quantity effect interacting with age—not a direct AMH measurement of embryo health.
PGT-A results, embryo grading, and AMH answer different questions. None should be used as a substitute for the others.
“Improving AMH” Is Often the Wrong Treatment Goal
Supplements, PRP, stem-cell procedures, diets, and other interventions are promoted with claims that they raise AMH or rejuvenate the ovary.
A laboratory value can fluctuate without a clinically meaningful increase in eggs or live birth. Raising AMH is not itself a patient outcome.
Patients should ask:
- Does the intervention increase usable eggs?
- Does it improve embryo development or cumulative live birth?
- Is the evidence from controlled studies?
- What are the risks and costs?
- Could it delay effective treatment?
No established treatment can make an older ovary biologically young or reliably create new eggs for clinical use.
The target should be the best use of the opportunity that exists—not cosmetic improvement of a marker.
Reserve Results Should Change Counselling, Not Human Worth
The language used around ovarian reserve can be damaging. Terms such as “empty ovaries,” “bad eggs,” or “no fertility” may be scientifically inaccurate and emotionally harmful.
Patients need direct information, including when prognosis is low. Accuracy does not require cruelty.
A responsible conversation may say:
- The expected response is likely to be limited.
- Few eggs may be retrieved, and some cycles may yield none.
- Age affects the chance that each embryo is chromosomally suitable.
- Treatment remains possible, but the probability and burden must be considered.
- There are options to repeat, modify, preserve, pause, seek another opinion, or stop.
The patient is not a hormone result.
International Patients Need Comparable Data
AMH results from different countries may use different units, assays, and reference ranges. A value should be submitted with:
- Unit of measurement
- Laboratory name and reference interval
- Test date
- Hormonal medication at the time
- Cycle and pregnancy context
- Previous results, if relevant
Antral follicle count reports should ideally include images, ovarian accessibility, cysts, and the counting method.
For patients who have undergone IVF, stimulation records and actual egg yield are often more valuable than repeating AMH immediately after arrival.
Remote review should convert the data into a realistic treatment expectation before travel decisions are made.
Five Questions for Every Ovarian-Reserve Result
At Jinemed, interpretation can be organised through five questions:
- Why was the test performed?
- What does it predict—egg quantity, stimulation response, or something else?
- How does age change the meaning of the result?
- Does the result agree with ultrasound and previous response?
- Which decision will change because of it?
If no decision changes, repeating or expanding testing may add anxiety rather than value.
What the Numbers Can—and Cannot—Tell Us
Age, AMH, AFC, FSH, and previous response each contribute to fertility counselling. None tells the whole story.
AMH and AFC are useful predictors of egg yield. Age remains a stronger predictor of egg competence and reproductive outcome. Previous stimulation shows how the ovaries actually responded. The complete fertility evaluation determines whether eggs can meet sperm, fertilise, implant, and continue as a pregnancy.
At Jinemed, ovarian-reserve testing is used to plan—not to pronounce a verdict.
The numbers can help choose medication, anticipate response, discuss timing, and prepare for uncertainty.
They cannot measure hope, guarantee an embryo, or decide on behalf of the patient whether treatment is worth attempting.